QSAR analysis of HIV-1 reverse transcriptase inhibitory 5-alkyl-2- [(aryl and alkyloxylcarbonylmethyl) thio]-6- (1-napthylmethyl) pyrimidin-4 (3H)-ones

International Journal of Virology

Volumn 6, Issue 2, 2010, Pages 100-108

  Karthikeyan, C ^a   Santosh, Dengale ^a   Hari Narayana Moorthy, N S ^b   Trivedi, Piyush ^a  

^a SHRI G S INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^b UNIVERSITY INSTITUTE OF TECHNOLOGY   (India)

Author keywords

HIV 1 reverse transcriptase inhibitors; MOE; NNRTIS; QSAR; S DABO

Indexed keywords

5 ALKYL 2 [(ARYL AND ALKYLOXYCARBONYLMETHYL)THIO] 6 (1 NAPHTHYLMETHYL)PYRIMIDIN 4 (3H)ONE DERIVATIVE; PYRIMIDINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; DRUG STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79959228504     PISSN: 18164900     EISSN: None     Source Type: Journal    
DOI: 10.3923/ijv.2007.19.27     Document Type: Article

References (34)

1. Bacheler, L.T., 1999. Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase. Drug Resist. Updates, 2: 56-67.
2. Balaji, S., C. Karthikeyan, N.S. Hari Narayan Moorthy and P. Trivedi, 2004. QSAR modelling of HIV-1 reverse transcriptase inhibition by benzoxazinones using a combination of P_VSA and pharmacophore feature descriptors. Bioorg. Med. Chem. Lett., 14: 6089-6094.
3. '-spiro-5-(4-amino-1",2-oxathiole-2,2-dioxide) (TSAO) derivatives of purine and pyrimidine nucleosides as potent and selective inhibitors of human immunodeficiency virus type 1. Antimicrob. Agents Chemother., 36: 1073-1080.
4. Cho, D.H., S.K. Lee, B.T. Kim and K.T. No, 2001. Quantitative Structure-Activity Relationship (QSAR) study of new fiuorovinyloxyacetamides. Bull. Korean Chem. Soc, 22: 388-394.
5. Darke, P.L. and J.R. Huff, 1994. Advances in Pharamacology. Augest, J., M.W. Ander, F. Murad (Eds.), San Diego, Academic, pp: 399-415.
6. De Clercq, E., 1995. Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J. Med. Chem., 38: 2491-2517.
7. De Clercq, E., 1998. The role of non-nucleoside reverses transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res., 38: 153-179.
8. De Clercq, E., 2000. Novel compounds in preclinical/early clinical development for the treatment of HIV infections. Rev. Med. Virol, 10: 255-277.
9. De Clercq, E., 2001. New developments in anti-HIV chemotherapy. II Farmaco, 56: 3-12.
10. De Clercq, E., 2002a. New anti-HIV agents and targets. Med. Res. Rev., 22: 531-565.
11. De Clercq, E., 2002b. New developments in anti-HIV chemotherapy. Biochim. Biophys. Acta, 1587:258-275.
12. Fujiwara, T., A. Sato, M. El-Farrash, S. Miki and K. Abe et al., 1998. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob. Agents Chemother., 42: 1340-1345.
13. Gayen, S., B. Debnath, S. Samantha and T. Jha, 2004. QSAR study on some anti-HIV HEPT analogues using physicochemical and topological parameters. Biorg. Med. Chem., 12: 1493-1503.
14. Goldman, M.E., J.H. Nunberg, J.A. O'Brien, J.C. Quintero and W.A. Schleif et al., 1991. Pyridone derivatives: Specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc. Natl. Acad. Sci. USA., 88: 6863-6867.
15. Hall, L.H. and L.B. Kier, 1991. The molecular connectivity chi indices and kappa shape indices in structure-property modeling. Rev. Comput. Chem., Vol. 2.
16. He, Y., C. Fener, S. Guangfu, W. Yueping, E. De Clercq, J. Balzarini and C. Pannecouque, 2004. 5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6- (1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series. Bioorg. Med. Chem. Lett., 14: 3173-3176.
17. Jonckheere, H., J. Anne and E. De Clercq, 2000. The HIV-1 reverse transcription (RT) process as target for RT inhibitors. Med. Res. Rev., 20: 129-154.
18. Kier, L.B. and L.H. Hall, 1977. Structure-activity studies on hallucinogenic amphetamines using molecular connectivity. J. Med. Chem., 20: 1631-1636.
19. Leonard, J. and K. Roy, 2004. Classical QSAR Modeling of HIV-1 Reverse Transcriptase Inhibitor 2-Amino-6-arylsulfonylbenzonitriles and Congeners. QSAR Combi. Sci., 23: 23-35.
20. Lin, A., 1997. QuaSAR-descriptors, Journal of Chemical Computing Group. http://www.chemcomp.com/Journal_of_CCG/Features/descr.htm.
21. Ludovici, D.W., M.J. Kukla, P.G. Grous, S. Krishnan and K. Andries et al., 2001. Evolution of anti-HIV drug candidates. Part 1: From R-Anilinophenylacetamide (RAPA) to imidazolyl thiourea (ITU). Bioorg. Med. Chem. Lett., 11: 2225-2228.
22. Mati, K. and V.S. Lobanov, 1996. Quantum-chemical descriptors in QSAR/QSPR studies. Chem. Rev., 96: 1027-1043.
23. MOE., 2002. Molecular modeling package developed by chemical Computing Group Inc., Canada.
24. Palella, F.J., K.M. Delaney, A.C. Moorman, M.O. Loveless, J. Fuhrer, G.A. Satten, D.J. Aschman and S.D. Holmberg, 1998. For the HIV outpatient study investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Eng. J. Med., 338: 853-860.
25. Pauwels, R., K. Andries, J. Desmijter, D. Schols and M.J. Kukla et al., 1990. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature, 343: 470-474.
26. Pauwels, R., K. Andries, Z. Debryser, P. Van Daele and D. Schols et al., 1993. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of R-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. USA., 90: 1711-1715.
27. Petitjean, M., 1992. Applications of the radius-diameter diagram to the classification of topological and geometrical shapes of chemical compounds. J. Chem. Inf. Comput. Sci., 32: 331-337.
28. Piot, P., M. Bartos, P.D. Ghys, N. Walker and B. Schwartlander, 2001. The global impact of HIV/AIDS. Nature, 410: 968-973.
29. Prabhakar, Y.S., V.R Soloman, RK. Rawal, M.K. Gupta and S.B. Katti, 2004. CP-MLR/PLS Directed structure-activity modeling of the HIV-1 RT inhibitory activity of 2,3-Diaryl-l,3-thiazolidin-4-ones. QSAR Combi. Sci., 23:234-244.
30. Prince, W., K. Moore, L. Cass, N. Dallow, A. Jones, J.P. Kleim, P. Mutch and M. St. Clair, 1999. GW420867X, a new non-nucleoside reverse transcriptase inhibitor (NNRTI)-initial phase I evaluation. Abstracts of the 12th International Conference on Antiviral Research, Jerusalem, Israel, March21-25, 41: A48-A50.
31. SYSTAT 10.2, 2003. A statistical package developed by SYSTAT software Inc, USA, 2003.
32. Tanaka, H., H. Takashima, M. Ubasawa, K. Sekiya, I. Nitta, M. Baba, S. Shigeta, R.T. Walker, E. De Clercq and T. Miyasaka, 1992. Synthesis and antiviral activity of l-[(2-hydroxyethoxy)-methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. J. Med. Chem., 35: 4713-4719.
33. VALSTAT., 2004. A Statistical program developed by Dr. Arun Kumar Gupta, SGSITS, Indore.
34. Wiener, H., 1947. Structural determination of paraffin boiling points. J. Am. Chem. Soc, 69: 17-20.